Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ceftezole is a semisynthetic first-generation cephalosporin antibiotic belonging to the beta-lactam class. It exhibits broad-spectrum antibacterial activity against many gram-positive and gram-negative bacteria, though it is not effective against Pseudomonas aeruginosa, Serratia marcescens, or Proteus vulgaris. Ceftezole acts by binding to and inactivating penicillin-binding proteins (PBPs) located on the inner membrane of bacterial cell walls. These PBPs are transpeptidases essential for peptidoglycan biosynthesis; their inhibition disrupts cell wall synthesis, leading to bacterial cell lysis and death[1][3][5][8]. In addition to its antibacterial effects, ceftezole has demonstrated potent alpha-glucosidase inhibitory activity in vitro as a reversible non-competitive inhibitor[3][8]. Clinically, it is used for treating susceptible infections such as septicemia; respiratory, biliary or genitourinary tract infections; skin and skin structure infections; endocarditis; and for surgical prophylaxis[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ceftezole.